AATF (Gene)

Organism:

Homo sapiens

Synonyms:AATF, BFR2, CHE-1, CHE1, DED, ENTREZ:26574, HGNC:19235, MIM:608463, NM_012138, NP_036270, XM_011524611, XP_011522913, XR_934439, apoptosis antagonizing transcription factor

Omim:OMIM:608463

Id:ENSG00000275700

Hgnc:HGNC:19235

Entrez:26574

Ensembl:ENSG00000275700

Description:apoptosis antagonizing transcription factor

The protein encoded by this gene was identified on the basis of its interaction with MAP3K12/DLK, a protein kinase known to be involved in the induction of cell apoptosis. This gene product contains a leucine zipper, which is a characteristic motif of transcription factors, and was shown to exhibit strong transactivation activity when fused to Gal4 DNA binding domain. Overexpression of this gene interfered with MAP3K12 induced apoptosis. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View AATF's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with AATF.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using AATF.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for AATF.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with AATF.

Results found

Linked to

	Label	Description
	GSE226525 GSE226527 HNRNPH2 knockout 6 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 10 V 5 CISPLATIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 0 V 3 PALMITIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 8 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE188728 GSE188730 BRG1 HSA BCL7 knockdown B cell 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 9 V 13 TRAMETINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE116810 5 V 1 SELINEXOR HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE162892 ISOX 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE125782 3 V 1 GLUTAMINE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 trametinib NF1 9 v 12 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE226525 GSE226527 HNRNPH2 knockout 6 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE216043 10 V 5 CISPLATIN HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 0 V 3 PALMITIC ACID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE48812 sulforaphane 8 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE188728 GSE188730 BRG1 HSA BCL7 knockdown B cell 3 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE213588 9 V 13 TRAMETINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE116810 5 V 1 SELINEXOR HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE162892 ISOX 3 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE125782 3 V 1 GLUTAMINE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE213588 trametinib NF1 9 v 12 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.